retatrutide glp-1 gip glucagon agonist Calling a “GLP-3” is usually a quick sign that you don't understand the underlying biology. Retatrutide is a NuSH-based triple agonist—it targets GLP-1, GIP, and receptors. Only one of those Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

The typical incretin-related adverse events were present - nausea (43%), vomiting (21%), and diarrhea (33%)

GLP-1 medications are administered subcutaneously (under the skin) into areas with adequate subcutaneous fattypically the abdomen, thigh, or upper arm

Inflammation can induce acute or chronic oxidative stress via cytosolic protein kinase C and calcium release

For example, one person might post, 'Ozempic made me so sick I quit after two weeks,' but its unclear if they started at too high a dose, skipped the titration schedule, or had underlying gastrointestinal issues

My Kardia reported AFib, but again I suspect it is mostly actually unsynchronised tachycardias which the Kardia cannot distinguish from AFib - this is certainly the view of the Brompton's arrhythmia nurses

The minimum protein target during Retatrutide treatment sits around 80 to 100 grams daily for most adults